Travoprost (Synonyms: AL-6221, Flu-Ipr, 16mtrifluoromethylphenoxy tetranor PGF2α isopropyl ester, Travoprost) |
Catalog No.GC37822
One-Click Copy Product Info
|
Travoprost는 전립선소 F2α 유사체의 합성 에스터 전약으로 IKir6.2/Sur2a 이온 채널을 억제하고 IC50 값은 3μM이다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 157283-68-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Travoprost는 전립선소 F2α 유사체의 합성 에스터 전약으로 IKir6.2/Sur2a 이온 채널을 억제하고 IC50 값은 3μM이다. Travoprost는 각막과 공막에 의해 활성 FP 전립선소 수용체 작용제로 가수분해돼서 소량망 유출 기능을 개선한다[2]. Travoprost는 생체 내 실험에서 안압을 감소시키는 점안제로 일반적으로 사용되고 있다[3].
체외 실험에서20µg/ml Travoprost로 20분간 처리할 때 원발성 인간 각막윤부 상피세포(LECs)의 생존율과 증식을 현저하게 억제하였다[4]. 35µg/ml로 72시간 처리 시 결막 유래 상피세포에서 CD31 및 CD54 발현을 현저하게 감소시켰다[5]. 0.313μg/ml로 20분간 처리한 무홍채증 각막윤부 기질세포(AN-LSCs)에서는 세포 내 MMP-9 단백질 수준과 PTGFR 및 JNK의 mRNA 수준이 상승한 것으로 나타났다[6].
References:
[1] Friesacher T, Houtman M J C, Chen X, et al. Development of IKatp ion channel blockers targeting sulfonylurea resitant mutant KIR6. 2 based channels for treating DEND syndrome[J]. Biophysical Journal, 2022, 121(3): 388a.
[2] Toris C B, Zhan G, Fan S, et al. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure[J]. Journal of glaucoma, 2007, 16(2): 189-195.
[3] Lim K S, Nau C B, O'Byrne M M, et al. Mechanism of action of Bimatoprost, Latanoprost, and Travoprost in healthy subjects: a crossover study[J]. Ophthalmology, 2008, 115(5): 790-795. e4.
[4] Li S, Stachon T, Liu S, et al. The effect of travoprost on primary human limbal epithelial cells and the siRNA-based aniridia limbal epithelial cell model, in vitro[J]. Plos one, 2025, 20(8): e0330492.
[5] Guenoun J M, Baudouin C, Rat P, et al. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells[J]. Investigative ophthalmology & visual science, 2005, 46(7): 2444-2450.
[6] Li S, Stachon T, Liu S, et al. Increased sensitivity of primary aniridia limbal stromal cells to travoprost, leading to elevated migration and MMP-9 protein levels, in vitro[J]. PloS one, 2025, 20(6): e0326967.
| 세포 실험 [1]: | |
세포 라인 | 인간 각막윤부 상피세포 (LECs) |
제조 방법 | 인간 각막윤부 상피세포 (LECs)를 6-웰 배양판의 각 웰에 접종하고 각 웰에 KGM3 배지 2.5ml를 첨가하였습니다. 세포가 완전하게 융합에 도달한 후 트립신-EDTA를 사용해서 세포를 분해한 후에 96-웰 판에 재접종하였습니다. LECs는 표준 배양 조건(37°C, 95% 습도, 5% CO2) 하에서 배양되었습니다. 세포는 다양한 농도의 Travoprost (0.078, 0.156, 0.313, 0.625, 1.25, 2.5, 5, 10, 20, 40μg/ml)로 20분간 처리된 후 생존율 분석을 실시하였습니다. |
반응 조건 | 0.078, 0.156, 0.313, 0.625, 1.25, 2.5, 5, 10, 20, 40μg/ml; 20 분 동안 |
응용 분야 | Travoprost 처리는 용량 의존적으로 LECs의 세포 생존율을 감소시켰습니다. |
References: | |
| Cas No. | 157283-68-6 | SDF | |
| Synonyms | AL-6221, Flu-Ipr, 16mtrifluoromethylphenoxy tetranor PGF2α isopropyl ester, Travoprost | ||
| Canonical SMILES | O=C(OC(C)C)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)COC2=CC=CC(C(F)(F)F)=C2)[C@H](O)C[C@@H]1O | ||
| Formula | C26H35F3O6 | M.Wt | 500.55 |
| Solubility | Ethanol: 60 mg/mL (119.87 mM); DMSO: ≥ 41.67 mg/mL (83.25 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9978 mL | 9.989 mL | 19.978 mL |
| 5 mM | 399.6 μL | 1.9978 mL | 3.9956 mL |
| 10 mM | 199.8 μL | 998.9 μL | 1.9978 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: An oil
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 32 reference(s) in Google Scholar.)